Brief: NextCell Pharma Completes Directed Issue To Strategic Partner

NextCell Pharma AB

22/01/2021 06:35

Jan 22 (Reuters) - NextCell Pharma AB  NXTCL.ST :
    * SAID ON THURSDAY CARRIES OUT DIRECTED ISSUE OF 286,666 NEW
SHARES TO POLSKI BANK KOMÓREK MACIERZYSTYCH S.A (PBKM)
    * SUBSCRIPTION PRICE AMOUNTS TO SEK 15 PER NEW SHARE, GIVING
CO
ABOUT SEK 4.3 MLN IN ISSUE PROCEEDS
    * SUBSCRIPTION PRICE HAS BEEN DETERMINED BY BOARD OF
DIRECTORS
AFTER NEGOTIATIONS WITH PBKM 
    * PRICE CORRESPONDS TO DISCOUNT OF ABOUT 9.4% TO
VOLUME-WEIGHTED
AVERAGE PRICE OF CO'S SHARES DURING PAST TEN TRADING DAYS
    * MAIN PURPOSE OF SHARE ISSUE IS TO PROVIDE CO WITH
STRATEGICALLY
IMPORTANT INVESTOR PBKM, WHICH IS EUROPE'S LARGEST STEM CELL
BANK AND IMPORTANT PARTNER OF CO

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nWkr2bG108
    
 Further company coverage:  NXTCL.ST  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00))